Credit Suisse Group reissued their outperform rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a report published on Wednesday morning, Briefing.com Automated Import reports.
Several other equities analysts have also commented on the stock. LADENBURG THALM/SH SH reaffirmed a buy rating on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. Zacks Investment Research raised shares of DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. BidaskClub lowered shares of Zai Lab from a hold rating to a sell rating in a research report on Wednesday, May 1st. B. Riley reaffirmed a buy rating on shares of Champion Iron in a research report on Wednesday, April 24th. Finally, ValuEngine raised shares of VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research report on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $7.47.
ACRX stock opened at $2.77 on Wednesday. The firm’s 50-day moving average price is $2.46. AcelRx Pharmaceuticals has a one year low of $1.99 and a one year high of $5.05. The company has a quick ratio of 4.91, a current ratio of 5.03 and a debt-to-equity ratio of 0.79.
Several institutional investors have recently made changes to their positions in ACRX. BlackRock Inc. raised its position in shares of AcelRx Pharmaceuticals by 196.6% in the 4th quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock valued at $5,386,000 after purchasing an additional 1,545,702 shares during the last quarter. Two Sigma Investments LP increased its holdings in AcelRx Pharmaceuticals by 820.9% in the 4th quarter. Two Sigma Investments LP now owns 559,408 shares of the specialty pharmaceutical company’s stock worth $1,292,000 after buying an additional 498,664 shares during the period. Barclays PLC acquired a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $805,000. Norges Bank acquired a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $578,000. Finally, Tibra Equities Europe Ltd acquired a new position in AcelRx Pharmaceuticals in the 1st quarter worth approximately $521,000. 15.53% of the stock is owned by hedge funds and other institutional investors.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Recommended Story: How is a management fee different from a performance fee?
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.